Entrepreneurship

We strive to use scientific research to solve problems around the world. For this reason, several companies have been started and patents filed by members or alumni from the group.

9 companies started since 2012
20122013–201820172018202220232025

Affinity AI

Founded 2025 · affinityai.org

Leveraging cutting-edge AI-driven protein design technologies to deliver custom, high-quality affinity reagents at unprecedented speed

Founders: Timothy P. Jenkins, Oliver Morell, Esperanza Rivera-de-Torre

Combotope Therapeutics

Combotope Therapeutics ApS is a biotech company (CRO) that develops antibodies against combotopes (combined glycotopes and epitopes), primarily for therapeutic purposes (e.g., therapeutic antibodies and CAR-T/M therapies).

Founders: Dr. Klas Ola Blixt, Dr. Søren Nyboe Jakobsen, Andreas H. Laustsen

Agrobiomics ApS

Founded 2022 · agrobiomics.bio

Agrobiomics is a BioAg company harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.

Founders: Andreas H. Laustsen, Jonas A. Jürgensen

VenomAid Diagnostics ApS

Founded 2018 · venomaid.com

VenomAid Diagnostics ApS is a biotech and medtech company developing diagnostic kits for snakebite envenomings based on antibody technologies.

Founders: Andreas H. Laustsen, Cecilie Knudsen, Rasmus U. W. Friis, Søren Helweg Dam, Aleksander M. Haack, Jonas A. Jürgensen

Chromologics ApS

Founded 2017 · chromologics.com

Chromologics ApS is a biotech company developing fungal fermentation processes for novel natural colors for use in both food and non-food applications.

Founders: Andreas H. Laustsen

Bactolife ApS

Founded 2017 · bactolife.com

Bactolife ApS is a biotech company developing protein-based products for prevention and treatment of gastrointestinal infections.

Founders: Andreas H. Laustsen, Sandra W. Thrane

Antag Therapeutics ApS

Founded 2017 · antagtherapeutics.com

Antag Therapeutics ApS is a biotech company developing biotherapeutics against metabolic diseases

Founders: Andreas H. Laustsen

VenomAb IVS

2013–2018 · LinkedIn

VenomAb IVS was a biotech company aiming towards developing novel snakebite antivenoms based on human monoclonal antibodies.

Founders: Andreas H. Laustsen, Mikael Engmark

Biosyntia ApS

Founded 2012 · biosyntia.com

Biosyntia ApS is a biotech company developing bacterial fermentation solutions for fine and specialty chemicals and novel screening systems based on synthetic biology.

Founders: Andreas H. Laustsen

Patents

We aim for our discoveries to reach the people who need them. Patents are one step on that route.

Nanobodies capable of cross-binding to several different elapid three-finger toxinsDamsbo A, Rivera-de-Torre E, Laustsen AHPriority 2023
  • EP4791771A1. Published 2026-08-19
  • EP23202838.1. Priority date: 2023-10-10
  • PCT/EP2024/078572. Filed 2024-10-10
In vivo neutralization of coral snake venoms with an oligoclonal nanobody mixtureBenard-Valle M, Ljungars A, Laustsen AHPriority 2023
  • WO2025040765A1. Published 2025-02-27
  • EP23192644.5. Priority date: 2023-08-22
  • PCT/EP2024/073607. Priority date: 2024-08-22
pH-sensitive antibodiesWade J, Laustsen AHPriority 2023
  • EP4709748A1. Published 2026-03-18
  • EP23172448.5. Priority date: 2023-05-09
Single domain antibodies to reduce the risk of Cholera infectionThrane SW, Petersson M, Laustsen AHPriority 2022
  • WO2024121125A1. Published 2024-06-13
  • EP22211729.3. Priority date: 2022-12-06
sdAb-CBM fusion protein bound to polysaccharide polymerLaustsen M, Christensen S, Thrane SW, Duzs A, Jørgensen C, Laustsen AHPriority 2022
  • EP4601745A1. Published 2025-08-20
  • WO2024/079210. PCT/EP2023/078242. Published: 2024-04-18
  • EP22201628.9. Priority date: 2022-10-14
Antibodies against snake toxins causing muscle and/or tissue damageLaustsen AH, Sørensen CV, Lomonte B, Fernández JPriority 2022
  • EP4302836A1. Published 2024-01-10
  • EP22182860.1. Priority date: 2022-07-04
Allergy vaccines based on consensus allergensLaustsen AH, Rivera-de-Torre E, Jenkins TPPriority 2022
  • US20250367280A1. Published 2025-12-04
  • EP22179541.2. Priority date: 2022-06-17
Neutralisation of α-neurotoxins using human recombinant IgG antibodiesLaustsen AH, Ledsgaard L, Lomonte B, Gutiérrez JM, Karatt-Vellatt A, McCafferty JPriority 2022
  • WO2023209212A1. Published 2023-11-02
  • EP22170880.3. Priority date: 2022-04-29
  • PCT/EP2023/061365. Filed 2023-05-01
Fusion proteins and their use against EimeriaLaustsen AH, Thrane SW, Førgaard C, Kofoed LVPriority 2022
  • WO2023194388A1. Published 2023-10-12
  • EP22196738.3. Priority date: 2022-04-07
Single domain antibodies for prevention of Clostridium difficile infectionLaustsen AH, Thrane SW, Rodriguez-Rodriguez ER, Laustsen MAPriority 2021
  • EP4441092A2. Published 2024-10-09
  • WO2023/099711. РСТ/EP2022/084159. Published: 2023-06-08
  • EP21211996. Priority date: 2021-12-02
Pathogen binding proteinsLaustsen AH, Thrane SW, Laustsen MAPriority 2019
  • US12441783B2. Granted and published 2025-10-14
  • WO2020/144164. PCT/EP2020/050183. Published: 2020-07-16
  • PCT/DK2019/050004. Filed 2019-01-07. Updated 2020-02-07
Myotoxin-neutralizing peptidesLaustsen AH, Lohse B, Lomonte B, Gutiérrez JM, Fernández J, Oscoz SPriority 2018
  • US20210070804A1. Published 2021-03-11
  • EP18164297.6. Priority date: 2018-03-27
  • PCT/EP2019/057522. Filed 2019-03-26
  • BR112020019213A2. Published 2021-01-05
  • US20210070804A1. Published 2021-03-11

5 further applications are on file but not yet published, so they are not listed here.